Compare HIT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIT | PLRX |
|---|---|---|
| Founded | 1964 | 2015 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 68.7M |
| IPO Year | N/A | 2020 |
| Metric | HIT | PLRX |
|---|---|---|
| Price | $1.07 | $1.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $3.25 | $2.67 |
| AVG Volume (30 Days) | 55.0K | ★ 694.7K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $69.63 | N/A |
| P/E Ratio | $52.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $1.05 |
| 52 Week High | $4.01 | $1.95 |
| Indicator | HIT | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 41.60 |
| Support Level | $1.01 | N/A |
| Resistance Level | $1.16 | $1.37 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 22.22 | 24.00 |
Health In Tech Inc is an AI-enabled insurance technology platform company that offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, it streamlines the underwriting, sales, and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs), and third-party administrators (TPAs). The company's platform serves as a marketplace for brokers, TPAs, MGUs and carriers with self-funded health insurance options for employers. The platform includes functions such as plan customization, stop-loss quoting, underwriting, claims administration, and reporting integration.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.